Polymorphisms in the enhancer region of the thymidylate synthase gene are associated with thymidylate synthase levels in normal tissues but not in malignant tissues of patients with colorectal cancer

Robert Mauritz, Elisa Giovannetti, Ines J. Beumer, Kees Smid, Cees J. Van Groeningen, Herbert M. Pinedo, Godefridus J. Peters

Research output: Contribution to journalArticle

Abstract

Background: The enhancer region of the thymidylate synthase (TS) gene (TSER) contains a polymorphic tandem repeat sequence (2 or 3 repeats, 2R or 3R) and a single-nucleotide polymorphism (G > C) within the second repeat of the 3R alleles which might influence TS expression/activity and response to fluoropyrimidines. However, clinical studies in patients with colorectal cancer (CRC) failed to find a consistent relationship between TSER polymorphisms and protein levels as well as with clinical outcome. The analysis of the relationship between TSER genotype and TS mRNA and activity in normal and malignant tissues might explain the previous controversial data and help in the selection of useful markers to predict drug response and/or toxicity. Materials and Methods: To address this issue, we studied TSER genotype, TS expression, and activity with specific polymerase chain reaction and activity assays (TS catalytic activity and FdUMP binding) in normal (liver, mucosa) and malignant (primary tumor and liver metastasis) tissues from 83 patients with CRC. Results: No correlation between TSER genotype and TS mRNA and protein levels was observed in malignant tissues. In contrast, normal tissues harboring one or two 3RG alleles were characterized by higher TS protein levels (2.4-fold; P = .008) and catalytic activity (P <.05) compared with the other TSER genotypes. Conclusion: These results suggest that TSER polymorphisms do not predict tumoral TS levels possibly depending on altered TS regulation in cancer tissues, and might explain the lack of clear correlation with clinical outcome after chemotherapy with fluoropyrimidines. However, the relationship between TS phenotype and TSER genotype in normal tissues warrants further investigations in large-scale prospective studies evaluating TS genotype and fluoropyrimidine tolerability.

Original languageEnglish (US)
Pages (from-to)146-154
Number of pages9
JournalClinical Colorectal Cancer
Volume8
Issue number3
DOIs
StatePublished - Jul 1 2009
Externally publishedYes

Fingerprint

Thymidylate Synthase
Colorectal Neoplasms
Genes
Genotype
Fluorodeoxyuridylate
Alleles
Messenger RNA
Proteins
Tandem Repeat Sequences
Liver
Single Nucleotide Polymorphism
Neoplasms
Mucous Membrane
Prospective Studies

Keywords

  • 3R allele
  • 5-Fluorouracil
  • Capecitabine
  • Fluoropyrimidines
  • Leucovorin
  • Molecular marker
  • TSER genotype

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

Polymorphisms in the enhancer region of the thymidylate synthase gene are associated with thymidylate synthase levels in normal tissues but not in malignant tissues of patients with colorectal cancer. / Mauritz, Robert; Giovannetti, Elisa; Beumer, Ines J.; Smid, Kees; Van Groeningen, Cees J.; Pinedo, Herbert M.; Peters, Godefridus J.

In: Clinical Colorectal Cancer, Vol. 8, No. 3, 01.07.2009, p. 146-154.

Research output: Contribution to journalArticle

Mauritz, Robert ; Giovannetti, Elisa ; Beumer, Ines J. ; Smid, Kees ; Van Groeningen, Cees J. ; Pinedo, Herbert M. ; Peters, Godefridus J. / Polymorphisms in the enhancer region of the thymidylate synthase gene are associated with thymidylate synthase levels in normal tissues but not in malignant tissues of patients with colorectal cancer. In: Clinical Colorectal Cancer. 2009 ; Vol. 8, No. 3. pp. 146-154.
@article{d590fae3694546f9b1055b99bbf60b6f,
title = "Polymorphisms in the enhancer region of the thymidylate synthase gene are associated with thymidylate synthase levels in normal tissues but not in malignant tissues of patients with colorectal cancer",
abstract = "Background: The enhancer region of the thymidylate synthase (TS) gene (TSER) contains a polymorphic tandem repeat sequence (2 or 3 repeats, 2R or 3R) and a single-nucleotide polymorphism (G > C) within the second repeat of the 3R alleles which might influence TS expression/activity and response to fluoropyrimidines. However, clinical studies in patients with colorectal cancer (CRC) failed to find a consistent relationship between TSER polymorphisms and protein levels as well as with clinical outcome. The analysis of the relationship between TSER genotype and TS mRNA and activity in normal and malignant tissues might explain the previous controversial data and help in the selection of useful markers to predict drug response and/or toxicity. Materials and Methods: To address this issue, we studied TSER genotype, TS expression, and activity with specific polymerase chain reaction and activity assays (TS catalytic activity and FdUMP binding) in normal (liver, mucosa) and malignant (primary tumor and liver metastasis) tissues from 83 patients with CRC. Results: No correlation between TSER genotype and TS mRNA and protein levels was observed in malignant tissues. In contrast, normal tissues harboring one or two 3RG alleles were characterized by higher TS protein levels (2.4-fold; P = .008) and catalytic activity (P <.05) compared with the other TSER genotypes. Conclusion: These results suggest that TSER polymorphisms do not predict tumoral TS levels possibly depending on altered TS regulation in cancer tissues, and might explain the lack of clear correlation with clinical outcome after chemotherapy with fluoropyrimidines. However, the relationship between TS phenotype and TSER genotype in normal tissues warrants further investigations in large-scale prospective studies evaluating TS genotype and fluoropyrimidine tolerability.",
keywords = "3R allele, 5-Fluorouracil, Capecitabine, Fluoropyrimidines, Leucovorin, Molecular marker, TSER genotype",
author = "Robert Mauritz and Elisa Giovannetti and Beumer, {Ines J.} and Kees Smid and {Van Groeningen}, {Cees J.} and Pinedo, {Herbert M.} and Peters, {Godefridus J.}",
year = "2009",
month = "7",
day = "1",
doi = "10.3816/CCC.2009.n.024",
language = "English (US)",
volume = "8",
pages = "146--154",
journal = "Clinical Colorectal Cancer",
issn = "1533-0028",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Polymorphisms in the enhancer region of the thymidylate synthase gene are associated with thymidylate synthase levels in normal tissues but not in malignant tissues of patients with colorectal cancer

AU - Mauritz, Robert

AU - Giovannetti, Elisa

AU - Beumer, Ines J.

AU - Smid, Kees

AU - Van Groeningen, Cees J.

AU - Pinedo, Herbert M.

AU - Peters, Godefridus J.

PY - 2009/7/1

Y1 - 2009/7/1

N2 - Background: The enhancer region of the thymidylate synthase (TS) gene (TSER) contains a polymorphic tandem repeat sequence (2 or 3 repeats, 2R or 3R) and a single-nucleotide polymorphism (G > C) within the second repeat of the 3R alleles which might influence TS expression/activity and response to fluoropyrimidines. However, clinical studies in patients with colorectal cancer (CRC) failed to find a consistent relationship between TSER polymorphisms and protein levels as well as with clinical outcome. The analysis of the relationship between TSER genotype and TS mRNA and activity in normal and malignant tissues might explain the previous controversial data and help in the selection of useful markers to predict drug response and/or toxicity. Materials and Methods: To address this issue, we studied TSER genotype, TS expression, and activity with specific polymerase chain reaction and activity assays (TS catalytic activity and FdUMP binding) in normal (liver, mucosa) and malignant (primary tumor and liver metastasis) tissues from 83 patients with CRC. Results: No correlation between TSER genotype and TS mRNA and protein levels was observed in malignant tissues. In contrast, normal tissues harboring one or two 3RG alleles were characterized by higher TS protein levels (2.4-fold; P = .008) and catalytic activity (P <.05) compared with the other TSER genotypes. Conclusion: These results suggest that TSER polymorphisms do not predict tumoral TS levels possibly depending on altered TS regulation in cancer tissues, and might explain the lack of clear correlation with clinical outcome after chemotherapy with fluoropyrimidines. However, the relationship between TS phenotype and TSER genotype in normal tissues warrants further investigations in large-scale prospective studies evaluating TS genotype and fluoropyrimidine tolerability.

AB - Background: The enhancer region of the thymidylate synthase (TS) gene (TSER) contains a polymorphic tandem repeat sequence (2 or 3 repeats, 2R or 3R) and a single-nucleotide polymorphism (G > C) within the second repeat of the 3R alleles which might influence TS expression/activity and response to fluoropyrimidines. However, clinical studies in patients with colorectal cancer (CRC) failed to find a consistent relationship between TSER polymorphisms and protein levels as well as with clinical outcome. The analysis of the relationship between TSER genotype and TS mRNA and activity in normal and malignant tissues might explain the previous controversial data and help in the selection of useful markers to predict drug response and/or toxicity. Materials and Methods: To address this issue, we studied TSER genotype, TS expression, and activity with specific polymerase chain reaction and activity assays (TS catalytic activity and FdUMP binding) in normal (liver, mucosa) and malignant (primary tumor and liver metastasis) tissues from 83 patients with CRC. Results: No correlation between TSER genotype and TS mRNA and protein levels was observed in malignant tissues. In contrast, normal tissues harboring one or two 3RG alleles were characterized by higher TS protein levels (2.4-fold; P = .008) and catalytic activity (P <.05) compared with the other TSER genotypes. Conclusion: These results suggest that TSER polymorphisms do not predict tumoral TS levels possibly depending on altered TS regulation in cancer tissues, and might explain the lack of clear correlation with clinical outcome after chemotherapy with fluoropyrimidines. However, the relationship between TS phenotype and TSER genotype in normal tissues warrants further investigations in large-scale prospective studies evaluating TS genotype and fluoropyrimidine tolerability.

KW - 3R allele

KW - 5-Fluorouracil

KW - Capecitabine

KW - Fluoropyrimidines

KW - Leucovorin

KW - Molecular marker

KW - TSER genotype

UR - http://www.scopus.com/inward/record.url?scp=69549138586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69549138586&partnerID=8YFLogxK

U2 - 10.3816/CCC.2009.n.024

DO - 10.3816/CCC.2009.n.024

M3 - Article

C2 - 19632929

AN - SCOPUS:69549138586

VL - 8

SP - 146

EP - 154

JO - Clinical Colorectal Cancer

JF - Clinical Colorectal Cancer

SN - 1533-0028

IS - 3

ER -